Neurocrine Biosciences (NBIX) CLO Lippoldt Sells $1.7M of Stock
Darin Lippoldt, Chief Legal Officer at Neurocrine Biosciences, sold 9,800 shares valued at over $1.67 million on June 29, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Darin Lippoldt, Chief Legal Officer at Neurocrine Biosciences, Inc. ($NBIX), sold 9,800 shares at an average price of $170.16, worth about $1.67 million, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $NBIX is up 2.4% after 1 week, up 6.3% after 1 month and down 20.2% to date (from the $170 close on Jun 29, 2026).
NBIX
Neurocrine Biosciences, Inc.
Key Points
- On June 29, 2026, Darin Lippoldt sold 9,800 shares of Neurocrine Biosciences for about $1.67 million, following two recent share purchases.
- Neurocrine Biosciences' stock closed at $168.54 on June 28, 2026, slightly above its 50-day moving average of $161.57, indicating stable trading conditions.
- Analysts have a strong buy consensus on Neurocrine Biosciences, with an average price target of $208.40 from 29 opinions.
Get $NBIX trade alerts by text
We text you when insiders, Congress or big funds trade $NBIX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Neurocrine Biosciences, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Neurocrine Biosciences, Inc.
On June 29, 2026, Darin Lippoldt, the Chief Legal Officer of Neurocrine Biosciences, Inc. (Nasdaq: NBIX), sold 9,800 shares valued at approximately $1.67 million. The transaction took place at an average price of $170.16 per share. This sale comes just days after Lippoldt bought 200 shares on June 26, 2026, for about $16,298.
Recent Purchase by Lippoldt
Lippoldt's previous purchase of 200 shares for $81.49 each reflects a commitment to the company, although selling a larger quantity soon after raises questions about his outlook on Neurocrine's future. His recent trades could suggest a strategic repositioning, especially considering the timing so close to the earnings report expected on October 28, 2026.
Analysts Set New Price Targets
Analysts seem to have a positive outlook for Neurocrine Biosciences. On October 16, 2026, Needham reiterated its "Buy" rating with a price target of $204. BMO Capital maintains a "Market Perform" rating with a target of $150. Other firms like UBS and RBC Capital also have positive ratings, indicating a general consensus of optimism about the stock.
Stock Performance Insights
Following Lippoldt's recent sale, Neurocrine shares were trading around $168.54, slightly above its 50-day moving average of $161.57. This position suggests that the stock remains stable in the market despite fluctuations, given its 52-week range of $122.14 to $186.12. The stock's strong performance is noteworthy, especially with several analysts projecting targets well above the current price level.
What Neurocrine Biosciences, Inc. Does
Neurocrine Biosciences, Inc. focuses on developing innovative treatments for various neurological and psychiatric conditions. Their products include INGREZZA for tardive dyskinesia and Orilissa for endometriosis, among others. This strategic focus on specialized pharmaceuticals positions the company well within the healthcare sector.
What's Ahead for Neurocrine Biosciences, Inc.
As Neurocrine prepares for its next earnings report on October 28, 2026, investors will be watching closely for any indications of the company’s growth trajectory. Lippoldt's recent sale could be a point of interest as stakeholders assess the implications of insider trading on market sentiment. Remember, the recent transactions reflect past holdings and might not represent current positions.
Related Filing Alerts
Source: Darin Lippoldt's Form 4 filing on $NBIX (Jun 29, 2026). Find the original filing: NBIX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts